The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
NCT06967558
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PreDiabetes
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 25 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- December 15, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Mayo Clinic in Rochester · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.